What is the cost of Exparel?
The cost of Exparel can vary significantly depending on factors such as insurance coverage, geographic location, and the healthcare provider. While specific retail prices are not publicly disclosed by the manufacturer, a single-dose vial of Exparel can range from approximately $300 to over $500 [1].
How does insurance affect Exparel's price?
Insurance coverage plays a crucial role in a patient's out-of-pocket expense for Exparel. Many insurance plans may cover a portion of the cost, but this coverage can differ widely. Patients are advised to consult their insurance provider to understand their specific benefits and potential co-pays or deductibles associated with Exparel. For those without insurance, or with plans that offer limited coverage, the full cost can be substantial [1].
Are there programs to help with Exparel costs?
For eligible patients, the manufacturer offers financial assistance programs. These programs may include co-pay cards or patient assistance programs designed to reduce the financial burden of Exparel. Information on these programs is typically available through the drug's official website or by speaking with a healthcare provider [1].
When does Exparel's patent expire?
Exparel (bupivacaine liposome injectable suspension) has patent protection. According to DrugPatentWatch.com, the key patents covering Exparel are expected to expire at various times, with some of the later-expiring patents extending into the late 2020s and early 2030s [2]. Patent expiration dates are critical for the potential introduction of generic or biosimilar alternatives, which could influence future pricing.
What is Exparel used for?
Exparel is a non-opioid local anesthetic that is injected at the surgical site to provide pain relief for several days following a procedure. It is used to manage post-operative pain in various surgical settings, including orthopedic surgeries, abdominal surgeries, and hernia repairs [1].
How does Exparel work?
Exparel utilizes proprietary DepoFoam technology, which encapsulates the anesthetic in a lipid-based matrix. This formulation allows for the slow, sustained release of bupivacaine over an extended period, providing prolonged pain control compared to traditional local anesthetics that are rapidly metabolized or cleared from the injection site [1].
What are the risks associated with Exparel?
Like all medications, Exparel carries potential risks and side effects. Common side effects include constipation, nausea, vomiting, and headache. More serious risks can include nerve damage if injected into a blood vessel, allergic reactions, and potentially serious cardiovascular and central nervous system events, especially with higher doses or accidental intravascular injection. Healthcare providers are responsible for administering Exparel appropriately to mitigate these risks [1].
What are the alternatives to Exparel for pain management?
Alternatives to Exparel for post-operative pain management include oral pain medications (such as non-steroidal anti-inflammatory drugs or opioids), other injectable local anesthetics with shorter durations of action, and multimodal pain management strategies that combine different approaches to minimize opioid use. The choice of pain management strategy is individualized based on the surgical procedure, patient factors, and physician recommendations [1].
Who manufactures Exparel?
Exparel is manufactured by The Medicines Company, which was acquired by Novartis in 2019 [1].